Follow Invezz on Telegram , Twitter , and Google News for instant updates >Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) is up a whopping 75% today after ONO Pharmaceutical (TYO: 4528) announced plans of buying it for $2.4 billion. Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Deciphera Pharmaceuticals stock valued at $25.60Copy link to sectionThe cash offer values each share of Deciphera Pharmaceuticals at $25.60. Gyo Sagara – the chief executive of ...

Deciphera Pharmaceuticals (NASDAQ:DCPH) stock is rising higher on Monday after signing a $2.4 billion acquisition agreement with ONO Pharmaceutical.This deal has ONO Pharmaceutical acquiring Deciphera Pharmaceuticals for $25.60 per share in cash. The company will do so through a tender offer for DCPH shares. That will see Deciphera Pharmaceuticals merge with a wholly-owned subsidiary of ONO Pharmaceutical.The offer for DCPH stock represents a 74.7% premium over its prior closing price on Friday. It’s also a ...

A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH) . Shares have added about 20.8% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Deciphera Pharmaceuticals, Inc. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Deciphera Q4 ...

Deciphera Pharmaceuticals, Inc. (DCPH) closed the last trading session at $16.91, gaining 18% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.11 indicates a 48.5% upside potential.The average comprises nine short-term price targets ranging from a low of $14 to a high of $34, with a standard deviation of $6.01. While the lowest estimate indicates a decline of 17.2% from the curr ...

Deciphera Pharmaceuticals, Inc. (DCPH) closed the last trading session at $15.73, gaining 6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.11 indicates a 59.6% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $6.01. While the lowest estimate of $14 indicates a 11% decline from the current price level, the most optimistic ...

Deciphera Pharmaceuticals, Inc. (DCPH) reported fourth-quarter 2023 loss of 54 cents per share, narrower than the Zacks Consensus Estimate of a loss of 58 cents. In the year-ago quarter, DCPH had incurred a loss of 60 cents per share.Net revenues were $48.3 million, which beat the Zacks Consensus Estimate of $46 million. The figure rose almost 33% year over year.Quarter in DetailTotal revenues comprise net product and collaboration revenues for Qinlock (ripretinib). Deciphera’s sole marketed drug, Qinlock, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________ ______________________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38219 ______________ ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 8:00 AM ET on Tuesday, February 6, 2024 ...

Financial Data and Key Metrics Changes - The company reported a record QINLOCK sales of $41.8 million for Q3 2023, representing a 29% year-over-year increase and a 12% quarter-over-quarter increase [13][39] - Global net product revenue for QINLOCK included $32.7 million from the U.S., which is a 33% increase year-over-year and a 13% increase quarter-over-quarter [13][39] Business Line Data and Key Metrics Changes - Vimseltinib achieved a 40% overall response rate at week 25 in the MOTION study, compared to 0% for placebo, with a p-value of less than 0.0001 [28][62] - The median treatment duration for Vimseltinib increased to approximately 25.1 months in the Phase I study and 21 months in Cohort A, with the longest patient on treatment for nearly 4 years [33][34] Market Data and Key Metrics Changes - The U.S. market opportunity for Vimseltinib is estimated at $500 million based on 1,400 incident patients, with additional opportunities in the EU where there are no approved therapies for TGCT [8][9] - The company noted a significant overlap of 70% to 80% between oncologists treating TGCT and those treating GIST, which could enhance commercial strategies [7][8] Company Strategy and Development Direction - The company plans to submit a New Drug Application (NDA) for Vimseltinib in the U.S. in Q2 2024 and a Marketing Authorization Application (MAA) in the EU shortly thereafter [4][48] - The strategic focus includes expanding the commercial footprint of QINLOCK and Vimseltinib, with expectations of exceeding $1 billion in peak global revenue from both products [15][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of Vimseltinib to change the standard of care in TGCT, highlighting its favorable safety profile compared to existing therapies [12][25] - The company remains committed to advancing its pipeline, with plans to file Investigational New Drug (IND) applications for new candidates in the near future [18][40] Other Important Information - The company ended Q3 2023 with approximately $377 million in cash and cash equivalents, maintaining a cash runway into 2026 [39] - The MOTION study results were described as transformative, with a strong emphasis on patient-reported outcomes and quality of life improvements [60][92] Q&A Session Summary Question: Can you discuss your confidence in the pivotal overall response rate reaching the long-term response rate observed in Phase I? - Management expressed optimism that the response rate could increase over time, citing a starting point of 40% in the MOTION study compared to 38% in previous studies [51][62] Question: Is there a difference between the Phase I and Phase II patient populations that explains the treatment duration delta? - The difference in treatment duration was attributed to the enrollment timing, with Cohort A catching up as more data becomes available [89] Question: Are there plans for trials in neoadjuvant-adjuvant settings for Vimseltinib? - While there is theoretical potential for Vimseltinib in earlier settings, no specific plans have been announced yet [90][94] Question: What are the expectations for off-label use of QINLOCK in the second-line setting? - Management noted that recent data and NCCN listings have positively impacted off-label use, but future trends will need to be monitored [58][99] Question: How does the safety profile of Vimseltinib compare to pexidartinib? - Management highlighted that Vimseltinib does not exhibit the cholestatic hepatotoxicity seen with pexidartinib, which could influence prescribing decisions [97][98]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q Quarterly Report on Form 10-Q for Deciphera Pharmaceuticals, Inc. for Q3 2023, confirming filer status and trading symbol - Filing Type: **Quarterly Report on Form 10-Q** for the period ended September 30, 2023[2](index=2&type=chunk) - Registrant: **Deciphera Pharmaceuticals, Inc.**[3](index=3&type=chunk) - Trading Symbol: **DCPH** on The Nasdaq Global Select Market[3](index=3&type=chunk) - Filer Status: **Large accelerated filer**[4](index=4&type=chunk) - Outstanding Shares (as of Oct 26, 2023): **80,123,138 shares of Common Stock** outstanding as of October 26, 2023[4](index=4&type=chunk) [SUMMARY OF MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS](index=3&type=section&id=SUMMARY%20OF%20MATERIAL%20RISKS%20ASSOCIATED%20WITH%20OUR%20BUSINESS) Overview of significant risks: QINLOCK commercialization, clinical trial failures, regulatory delays, competition, and financial viability - Commercialization Risk: No assurance of **successful commercialization of QINLOCK**, particularly in key European markets, or achieving expected revenue levels[9](index=9&type=chunk) - Clinical Trial Risk: The pivotal **Phase 3 INSIGHT study for QINLOCK** in second-line GIST may not be successful[9](index=9&type=chunk) - Regulatory & Supply Risk: Delays in **regulatory approvals** or **drug supply issues** could materially impair revenue generation[9](index=9&type=chunk) - Competition: **Substantial competition** may lead to others developing or commercializing products more successfully[9](index=9&type=chunk) - Financial Viability: **Significant operating losses** since inception, expected continued losses, and potential inability to achieve or maintain profitability[12](index=12&type=chunk) [FORWARD-LOOKING STATEMENTS](index=6&type=section&id=FORWARD-LOOKING%20STATEMENTS) Outlines forward-looking statements, emphasizing actual results may differ due to various risks and uncertainties - Disclaimer: All statements other than historical facts are **forward-looking** and subject to various risks and uncertainties[14](index=14&type=chunk) - Key Forward-Looking Areas: Key forward-looking areas include **successful commercialization of QINLOCK**, success and cost of **R&D plans for drug candidates** (including INSIGHT study and DCC-3116), **regulatory approvals**, ability to **obtain funding**, and **intellectual property protection**[15](index=15&type=chunk)[19](index=19&type=chunk) [PART I – FINANCIAL INFORMATION](index=7&type=section&id=PART%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) Presents unaudited consolidated financial statements, management's discussion, market risk, and controls for Q3 2023 [Item 1. Financial Statements (unaudited)](index=7&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) Provides unaudited consolidated financial statements: balance sheets, statements of operations, equity, cash flows, and notes [Consolidated Balance Sheets](index=8&type=section&id=Consolidated%20Balance%20Sheets) Shows changes in assets, liabilities, and stockholders' equity, with increases in total assets and equity **Total Assets:** | Metric | Sep 30, 2023 (in thousands) | Dec 31, 2022 (in thousands) | Change (in thousands) | | :----------------------- | :-------------------------- | :-------------------------- | :-------------------- | | Total Assets | $497,836 | $454,039 | +$43,797 | **Total Liabilities:** | Metric | Sep 30, 2023 (in thousands) | Dec 31, 2022 (in thousands) | Change (in thousands) | | :----------------------- | :-------------------------- | :-------------------------- | :-------------------- | | Total Liabilities | $116,166 | $112,348 | +$3,818 | **Total Stockholders' Equity:** | Metric | Sep 30, 2023 (in thousands) | Dec 31, 2022 (in thousands) | Change (in thousands) | | :----------------------- | :-------------------------- | :-------------------------- | :-------------------- | | Total Stockholders' Equity | $381,670 | $341,691 | +$39,979 | - Cash and Cash Equivalents: **Cash and cash equivalents increased** from **$64.7 million** at December 31, 2022, to **$108.1 million** at September 30, 2023[21](index=21&type=chunk) - Short-term Marketable Securities: **Short-term marketable securities decreased** from **$259.7 million** to **$231.0 million**[21](index=21&type=chunk) - Long-term Marketable Securities: **Long-term marketable securities increased** from **$14.6 million** to **$37.9 million**[21](index=21&type=chunk) [Consolidated Statements of Operations and Comprehensive Loss](index=9&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Details revenues, cost of sales, operating expenses, and net loss for Q3 and 9M 2023 and 2022 **Total Revenues:** | Metric | 3 Months Ended Sep 30, 2023 (in thousands) | 3 Months Ended Sep 30, 2022 (in thousands) | 9 Months Ended Sep 30, 2023 (in thousands) | 9 Months Ended Sep 30, 2022 (in thousands) | | :---------------- | :----------------------------------- | :----------------------------------- | :----------------------------------- | :----------------------------------- | | Product revenues, net | $41,820 | $32,318 | $112,362 | $92,624 | | Collaboration revenues | $1,493 | $3,656 | $2,700 | $5,067 | | **Total revenues** | **$43,313** | **$35,974** | **$115,062** | **$97,691** | **Total Cost and Operating Expenses:** | Metric | 3 Months Ended Sep 30, 2023 (in thousands) | 3 Months Ended Sep 30, 2022 (in thousands) | 9 Months Ended Sep 30, 2023 (in thousands) | 9 Months Ended Sep 30, 2022 (in thousands) | | :-------------------------------- | :----------------------------------- | :----------------------------------- | :----------------------------------- | :----------------------------------- | | Cost of sales | $1,286 | $3,344 | $1,947 | $5,525 | | Research and development | $62,463 | $47,485 | $175,524 | $139,755 | | Selling, general, and administrative | $33,252 | $30,026 | $97,311 | $87,972 | | **Total cost and operating expenses** | **$97,001** | **$80,855** | **$274,782** | **$233,252** | **Net Loss:** | Metric | 3 Months Ended Sep 30, 2023 (in thousands) | 3 Months Ended Sep 30, 2022 (in thousands) | 9 Months Ended Sep 30, 2023 (in thousands) | 9 Months Ended Sep 30, 2022 (in thousands) | | :---------------- | :----------------------------------- | :----------------------------------- | :----------------------------------- | :----------------------------------- | | Net loss | $(49,581) | $(43,043) | $(147,752) | $(132,996) | **Net Loss per Share (Basic and Diluted):** | Metric | 3 Months Ended Sep 30, 2023 | 3 Months Ended Sep 30, 2022 | 9 Months Ended Sep 30, 2023 | 9 Months Ended Sep 30, 2022 | | :--------------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | | Net loss per share—basic and diluted | $(0.58) | $(0.55) | $(1.75) | $(1.82) | [Consolidated Statements of Stockholders' Equity](index=10&type=section&id=Consolidated%20Statements%20of%20Stockholders'%20Equity) Details changes in stockholders' equity, including increased paid-in capital, common stock, and accumulated deficit - Additional Paid-in Capital: **Additional paid-in capital increased** from **$1.58 billion** at December 31, 2022, to **$1.76 billion** at September 30, 2023, primarily due to common stock offerings[26](index=26&type=chunk) - Accumulated Deficit: **Accumulated deficit increased** from **$(1.23) billion** at December 31, 2022, to **$(1.38) billion** at September 30, 2023, reflecting ongoing net losses[26](index=26&type=chunk) - Common Stock Shares Outstanding: **Common stock shares outstanding increased** from **67.6 million** shares at December 31, 2022, to **80.0 million** shares at September 30, 2023[26](index=26&type=chunk) [Consolidated Statements of Cash Flows](index=12&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Summarizes cash flows from operating, investing, and financing activities, showing a net increase in cash for 9M 2023 **Net Cash Flows Used in Operating Activities:** | Metric | 9 Months Ended Sep